Preliminary study results from ADACTA (ADalimumab ACTemrA) revealed that rheumatoid arthritis patients who received RoACTEMRA (tocilizumab) as monotherapy achieved a significantly greater reduction in disease activity (using DAS28) after 24 weeks than those given adalimumab (Humira) monotherapy. Monotherapy refers to treatment with a single drug, not in combination with any other drugs. In the U.S., RoACTEMRA is known as Actemra.
The Phase IV multi-center, randomized, double-blinded study known as ADACTA was designed to compare the reduction in signs and symptoms during RoACTEMRA monotherapy versus adalimumab monotherapy in 326 adult patients with severe active rheumatoid arthritis. Prior to the study, participants had not been treated with a biologic drug for rheumatoid arthritis. Since there are now several biologic drugs to choose from, studies pitting one against the other may help doctors and patients decide which drug is best to try.
- Actemra - What You Should Know
- The Facts of Humira
- Biologics Explained
- TNF Blockers - What You Need to Know
Photo by electricspace (iStockphoto)